News

First Quantum Minerals Achieves Resilience in Q4 2024

First Quantum Minerals Achieves Resilience in Q4 2024

First Quantum Minerals Reports Fourth Quarter Results

(In United States dollars, except where noted otherwise)

First Quantum Minerals Ltd. (TSX: FM) recently disclosed its financial performance for the fourth quarter of 2024, highlighting a net income of $99 million, equating to $0.12 earnings per share, along with adjusted earnings of $31 million or $0.04 per share.

Tristan Pascall, Chief Executive Officer of First Quantum, expressed gratitude to the team for their efforts during a challenging year, particularly due to the suspension at the Cobre Panamá mine. However, he remains optimistic about the outlook for 2025, anticipating constructive discussions with the Panamanian government regarding the mine's situation and the successful completion of the Kansanshi S3 Expansion in Zambia, which is expected to bolster the company’s financial stability and growth.

Q4 2024 Financial Overview

In Q4 2024, First Quantum reported a gross profit of $405 million and an EBITDA of $455 million. Compared to the third quarter of 2024, these results were a slight decline primarily driven by lower sales volumes of copper and gold, as well as a dip in realized copper prices. The total copper production reached 111,602 tonnes, a slight 4% decrease from the previous quarter, with a C1 cash cost of $1.68 per lb, reflecting a 7% quarter-over-quarter increase.

Operational Highlights and Project Updates

  • Cobre Panamá Update: The ongoing Preservation and Safe Management Program (P&SM) for the Cobre Panamá mine is awaiting necessary approvals from local authorities. The next international hearing concerning this matter has been rescheduled for February 2026.
  • Kansanshi S3 Expansion Update: Progress is on track for the Kansanshi S3 Expansion project, with construction at 62% completion as of the end of 2024, anticipated to reach operational readiness by mid-2025.
  • Zambia Power Update: First Quantum is implementing plans to secure reliable energy for its operations in Zambia, especially as it prepares for the Kansanshi S3 Expansion project start-up.
  • Board Leadership Changes: Robert Harding will retire as Chairman after the Annual General Meeting in May 2025, transitioning leadership to Kevin McArthur, who will take over his responsibilities.

Industry Challenges and Strategic Responses

First Quantum's financial results have been notably affected by the suspension of activities at the Cobre Panamá site, yet the company's proactive measures, including effective management of operational costs and strategic planning, have helped in maintaining a stable outlook. The anticipated completion of projects in both Zambia and Panama is expected to greatly enhance the company's growth and profitability going forward.

Future Production and Capital Guidance

Looking ahead, First Quantum is confident in its 2025 production guidance, maintaining the expected production figures for copper, gold, and nickel. Furthermore, for the next three years, the company outlined capital expenditures expected to support its operational goals and projects.

The estimated interest expenses associated with the company’s debt are projected to be between $600 million and $625 million for the full year 2025. The anticipated cash outflow on interest is approximately between $575 million and $600 million, excluding capitalized interest.

Frequently Asked Questions

1. What were First Quantum's net earnings for Q4 2024?

The net earnings attributable to shareholders were $99 million for Q4 2024.

2. How did the company's copper production perform in Q4 2024?

In Q4 2024, the total copper production was 111,602 tonnes, which is a 4% decrease from Q3 2024.

3. What updates were provided about the Cobre Panamá mine?

Progress on the Preservation and Safe Management Program is pending approval, with a hearing set for February 2026.

4. Who is succeeding Robert Harding as Chairman?

Kevin McArthur will succeed Robert Harding as Chairman following the 2025 Annual General Meeting.

5. What are the future production projections for First Quantum?

The company has maintained its production guidance for copper, gold, and nickel for the years 2025 to 2027, alongside planned capital expenditures.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading